Cargando…
MLC601 in vascular dementia: an efficacy and safety pilot study
BACKGROUND AND AIM: Vascular dementia (VaD) is the second most common cause of dementia and currently there is scarcity of therapies for VaD. We aimed to investigate the efficacy and safety of MLC601 in the treatment of VaD. METHODS: In this multicenter, pilot, randomized, double-blind trial, 82 pat...
Autores principales: | Pakdaman, Hossein, Amini Harandi, Ali, Gharagozli, Koroush, Abbasi, Mehdi, Ghaffarpour, Majid, Ashrafi, Farzad, Delavar Kasmaei, Hosein, Amini Harandi, Asghar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634376/ https://www.ncbi.nlm.nih.gov/pubmed/29042785 http://dx.doi.org/10.2147/NDT.S145047 |
Ejemplares similares
-
Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study
por: Pakdaman, Hossein, et al.
Publicado: (2017) -
Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial
por: Pakdaman, Hossein, et al.
Publicado: (2015) -
Efficacy and Safety of MLC601 in Patients with Mild to Moderate Alzheimer Disease: An Extension 4-Year Follow-Up Study
por: Pakdaman, Hossein, et al.
Publicado: (2018) -
MLC901 in hypoxic-ischemic brain injury patients: A double-blind, randomized placebo-controlled pilot study
por: Pakdaman, Hossein, et al.
Publicado: (2023) -
Frequency distribution of the first clinical symptoms in the Iranian population with multiple sclerosis
por: Gharagozli, Kurosh, et al.
Publicado: (2012)